---
title: Brain Tumor VQA Benchmark
url: https://www.emergentmind.com/topics/brain-tumor-vqa-benchmark
type: topic
---

# Brain Tumor VQA Benchmark

Visual question answering (VQA) benchmarks for brain tumors evaluate models’ ability to integrate multi-sequence magnetic resonance imaging (MRI) information with clinically relevant reasoning in neuro-oncology. These resources are pivotal for the development and assessment of vision-language models (VLMs) and multimodal large language models (MLLMs) for diagnostic, prognostic, and therapeutic tasks in brain tumor imaging. Benchmarks now encompass a range of tasks, question types, and annotation rigor reflecting advances in LLM/MLLM architectures, large-scale multi-center dataset integration, and domain-specific evaluation methodologies.

## 1. Dataset Construction and Composition

Brain tumor VQA benchmarks differ principally in imaging granularity, task scope, and annotation pipeline.

- **Cohort Sources and Modalities**: Key resources include curated subsets from the Brain Tumor Segmentation (BraTS) challenge (glioblastoma (GLI), meningioma (MEN), metastases (MET)), comprehensive public neuroimaging repositories (UCSF-PDGM, MM-NeuroOnco, NeuroQA, OmniBrainBench), as well as multi-institutional aggregations encompassing 2D slices, 3D volumes, and multi-modal data (MRI, CT, PET, SPECT) [2508.10865, 2511.00846, 2605.17140, 2605.20525, 2602.22955].

- **Sample Overview**:

  | Benchmark           | Main Cohorts             | Imaging Type                   | N(QA pairs) | Tumor Focus (%)   |
  |---------------------|--------------------------|-------------------------------|-------------|------------------|
  | GPT-5/BraTS         | BraTS-GLI, MEN, MET      | 3-plane MRI mosaics           | (not stated)| 100              |
  | OmniBrainBench      | 30 sources, 15 modalities| 2D slices, multi-modal        | 9,527       | ~22              |
  | UCSF-PDGM-VQA       | UCSF-PDGM (gliomas)      | 3D multi-sequence MRI         | 2,387       | 100              |
  | NeuroQA             | BraTS-GLI/–MEN           | 3D MRI volumes                | 5,746       | 100              |
  | MM-NeuroOnco        | 20 repositories, 8 tumors| 2D slices, 4 seqs, mask-level | ~200,000    | Focus            |

  Benchmarks span closed-ended multiple-choice (MCQ, Yes/No, numeric), open-ended and segmentation-augmented VQA, with structured radiology/clinical descriptors and mask-based ground truth typically used for annotation [2508.10865, 2511.00846, 2605.20525, 2602.22955].

- **Annotation Protocols**:
  - Rule-based, LLM-assisted, and expert-verified QA pipelines (e.g., GPT-4o/GPT-5.2, dual-VLM consensus, FreeSurfer/BraTS alignment, multi-pass clinical review)
  - Inter-annotator agreement above 95% (OmniBrainBench)
  - Rejection-aware labeling to prevent forced-choice bias (MM-NeuroOnco)

## 2. VQA Taxonomy, Task Definition, and Evaluation Approaches

Benchmarks categorize questions according to clinical reasoning granularity:

- **Question Types**:
  - **Visual/Perceptual**: directly observable MRI features such as enhancement, edema, mass effect, lesion boundary (e.g., "Does the lesion show ring enhancement?") [2508.10865, 2605.17140].
  - **Clinical Reasoning**: integrating visual cues with domain knowledge for differential diagnosis, grading, treatment planning (e.g., "What is the most likely tumor grade?") [2511.00846, 2605.20525].
  - **Measurement/Localization**: precise quantification (e.g., maximum dimension, lobe/region, margin definition) [2508.10865, 2605.20525].
  - **Open-ended**: free-form answers justifying findings or proposing management [2602.22955].

- **Evaluation Metrics**:
  - **Accuracy**: fraction of correctly answered QA pairs
    $$
    \mathrm{Acc} = \frac{1}{N}\sum_{i=1}^N \mathbf{1}(\hat{y}_i = y_i)
    $$
  - **Dice Coefficient**: lesion segmentation overlap (as needed)
    $$
    \mathrm{Dice} = \frac{2|P\cap G|}{|P| + |G|}
    $$
  - **F1-score**: multi-label grading/differential
    $$
    F_1 = 2 \frac{\mathrm{Precision}\times\mathrm{Recall}}{\mathrm{Precision}+\mathrm{Recall}}
    $$
  - **Shortcut Score (Editor's term)**: normalizes image-grounded gain above the text-only floor [2605.20525].
  - **Rejection Rate**:
    $$
    \mathrm{RejRate} = \frac{\#\{\hat y_i=\text{None}\}}{N}
    $$

- **QA Balance and Reliability**: Some benchmarks, such as NeuroQA and MM-NeuroOnco, implement answer-distribution refinement ensuring that text-only accuracy is forced to near chance, highlighting true visual reasoning [2605.20525, 2602.22955].

## 3. Baseline and State-of-the-Art Model Performance

Models are grouped by architecture and domain specialization, with all recent evaluations conducted in strict zero-shot or rejection-aware settings.

- **Proprietary MLLMs** (GPT-5 family, Gemini-2.5/3-Pro, Claude-Sonnet-4.0): macro-average accuracy for closed-ended VQA in the 40%–67% range; Gemini-3-Flash attains 40.9% on diagnosis QA (MM-NeuroOnco), GPT-5 achieves 44.19% on BraTS-based VQA (GLI/MEN/MET) [2508.10865, 2602.22955].
- **Medical MLLMs** (HuatuoGPT-V, Lingshu, MedVLM, MedGemma): typically 47–64% overall accuracy, yet 30–40% on preoperative assessment and diagnosis; Lingshu-32B reaches 63.2% on UCSF-PDGM-VQA [2511.00846, 2605.17140].
- **Open-source VLMs** (Qwen3-VL, Janus-Pro, InternVL): 45–56% overall but lowest (<40%) on complex tumor grading [2511.00846].
- **Text-only Baseline**: Often nearly equivalent performance (52.57% for Qwen3-8B), revealing language-prompt shortcut risk [2605.17140].

Across benchmarks, human experts (board-certified neuroradiologists) exhibit 88–91% accuracy, uniformly 30–40 percentage points above the best MLLMs [2508.10865, 2511.00846, 2605.17140].

| Model Category       | Tumor VQA Acc. (%)    | Source        |
|--------------------- |----------------------|---------------|
| GPT-5-mini           | 44.19                | [2508.10865]  |
| Gemini-3-Flash       | 40.9                 | [2602.22955]  |
| MedGemma-1.5 (multi) | 63.57                | [2605.17140]  |
| Qwen3-8B (text-only) | 52.57                | [2605.17140]  |
| Human Expert         | 88–91                | [2508.10865, 2511.00846, 2605.17140] |

## 4. Failure Modes, Biases, and Technical Limitations

Common weaknesses are observed among current VLMs/MLLMs, irrespective of model scale:

- **Modality Collapse**: VLMs often ignore visual input, defaulting to language priors. For example, Lingshu-32B and Med3DVLM both increase accuracy when presented with blank images; text-only baselines match or exceed vision-integrated models on closed questions [2605.17140].
- **Positional Bias**: Order of answer options causes 10–20% performance swings, independent of semantic content [2605.17140].
- **Inadequate 3D Context**: None of the evaluated models natively handle multi-series, full-volume MRI, leading to “single-slice” reasoning and fragmentation [2605.17140, 2602.22955].
- **Over-reliance on Forced-Choice**: Benchmarks lacking rejection or abstain options mask genuine uncertainty, encouraging overconfident guesses and hallucinations [2602.22955].
- **Clinical Implications**: Such biases risk inaccurate lesion quantification, localization, and mass effect assessment, with direct impact on surgical/radiotherapy targeting and prognosis [2605.17140].

## 5. Innovations in Evaluation Design and Annotation

Recent brain tumor VQA benchmarks introduce methodologies to actively counter shortcutting, hallucination, and annotation drift:

- **Image-Grounding Protocols**: NeuroQA mandates that image-absent accuracy falls to chance (~39.5%) and monitors for fabrications and hallucinations when no image is present [2605.20525].
- **Shortcut Suppression**: Answer-distribution refinement and balanced MCQ/YN insertion ensure any gain above the text-only floor reflects true image reasoning [2605.20525].
- **Rejection-Aware Evaluation**: MM-NeuroOnco’s “None of the above” reduces forced-choice bias, and ablation studies quantify the effect of rejection options on accuracy [2602.22955].
- **Deterministic Audit Pipelines**: Multi-stage rule pipelines (e.g., in NeuroQA, OmniBrainBench) enforce ground-truth alignment for all answers, with clinical, machine, and script-based review stages [2511.00846, 2605.20525].

## 6. Strategies for Performance Improvement and Future Research Trajectories

Several improvement paths are outlined across the benchmark literature:

- **Model Architecture**:
  - Native 3D/multisequence inputs; cross-slice or volumetric attention; region-of-interest guidance [2605.17140].
  - Enhanced multimodal fusion layers (pixel-level cross-attention) and integration of segmentation pre-processing [2508.10865, 2511.00846].
  - Chain-of-Thought regularization and prompt ensembling to stabilize reasoning [2602.22955, 2508.10865].
- **Training Curriculum**:
  - Domain-specific fine-tuning on neuro-oncology MRI corpora, using contrastive vision–language objectives [2511.00846, 2508.10865].
  - Multi-task pretraining: joint segmentation, detection, classification, and clinical VQA [2602.22955].
- **Benchmark and Workflow Expansion**:
  - Introduction of progressive clinical difficulty (single-image to longitudinal/temporal), open-ended and multi-turn dialogue VQA, human–AI interactive review, and explicit uncertainty quantification (ECE, Brier score) [2605.20525, 2602.22955].
  - Incorporation of segmentation-plus-VQA and linkage of clinical text (structured radiology findings) for complex numerics [2511.00846, 2605.20525].
- **Annotation and QA Rigor**:
  - Stratified sampling to reflect real-world case diversity, expert- and machine-audited QA, and reporting of inter-annotator agreement [2511.00846, 2605.20525, 2602.22955].

## 7. Clinical Significance and Benchmark Limitations

Despite increasing dataset scale, annotation rigor, and advancement in VLM/MLLM architecture, model accuracy in tumor-related VQA remains significantly below clinical acceptability (typically ≤ 50% vs ≥ 90% for human experts). Model errors—driven by insufficient visual grounding, shortcutting, and lack of volumetric context—impede reliable translation to high-stakes neuro-oncology workflows [2508.10865, 2511.00846, 2605.17140]. Current benchmarks may overestimate reliability when relying solely on closed-ended, forced-choice tasks without rejection-aware or calibration measures [2602.22955].

*This suggests that benchmarks must systematically audit for language priors, enforce image-grounded reasoning, and standardize uncertainty-aware metrics to catalyze clinically safe and actionable deployment.* A plausible implication is that future benchmarks will further expand diagnostic horizon (e.g., perfusion/diffusion imaging, molecular imaging, longitudinal studies), integrate complex multi-stage clinical reasoning, and require ensemble or human-in-the-loop models for robust, real-world performance [2511.00846, 2605.20525].

Source: https://www.emergentmind.com/topics/brain-tumor-vqa-benchmark